AKTIPAK Drug Patent Profile
✉ Email this page to a colleague
When do Aktipak patents expire, and when can generic versions of Aktipak launch?
Aktipak is a drug marketed by Biofrontera and is included in one NDA.
The generic ingredient in AKTIPAK is benzoyl peroxide; erythromycin. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; erythromycin profile page.
Summary for AKTIPAK
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | AKTIPAK at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for AKTIPAK
US Patents and Regulatory Information for AKTIPAK
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biofrontera | AKTIPAK | benzoyl peroxide; erythromycin | GEL;TOPICAL | 050769-001 | Nov 27, 2000 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |